Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

NCT02964507 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

124

Enrollment

INDUSTRY

Sponsor class

Stopped This study has been terminated due to meeting protocol defined futility.

Conditions

Neoplasms

Interventions

DRUG: GSK525762
DRUG: Placebo
DRUG: Fulvestrant

Sponsor

GlaxoSmithKline